Theralase® Technologies Inc. announced that its PDC technology has demonstrated a high kill rate in a preclinical analysis of coronavirus, Biological Safety Level ("BSL-2"). Theralase previously reported that the Company's PDC technology was effective in the destruction of Influenza H1N1 and Zika viruses at low nanomolar concentrations. These studies were expanded to include coronavirus (BSL-2). As a note, COVID-19 is caused by coronavirus (BSL-3), not coronavirus (BSL-2). An assay was established to measure coronavirus destruction and using this new assay the Theralase® PDC technology was able to destroy coronavirus (BSL-2) with drug doses 5 times lower than what was used to kill Influenza H1N1 and Zika viruses. These drug doses demonstrated a 99.995% destruction rate of the BSL-2 coronavirus and are significantly lower than those used by the Company to treat cancers; hence safe for human use. All coronaviruses are considered similar in their structure and these new results strongly suggest that Theralase®'s PDC will be highly effective against the SARS- CoV-2 (coronavirus (BSL-3)) virus responsible for COVID-19. In August 2020, Theralase® executed a Sponsored Research Agreement ("SRA") with the University of Manitoba ("UM") Medical Microbiology department to commence development of a coronavirus vaccine utilizing Theralase's patented and proprietary PDCs specifically TLD-1433. Currently the UM research is completing the preclinical (in-vitro) stage. Theralase® plans to commence an in-vivo small animal study later this year at another facility equipped to handle SARS-CoV-2 viruses and if successful commence human clinical studies in 2021, subject to suitable financing. The Company does not claim or profess that they have the ability to treat, cure or prevent the contraction of the COVID-19 Coronavirus.